Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

• Niels Weinhold,
• Hans J. Salwender,
• David A. Cairns,
• Marc S. Raab,
• George Waldron,
• Igor W. Blau,
• Uta Bertsch,
• Thomas Hielscher,
• Gareth J. Morgan,
• Anna Jauch,
• Faith E. Davies,
• Mathias Hänel,
• Gordon Cook,
• Christoph Scheid,
• Richard Houlston,
• Hartmut Goldschmidt,
• Graham Jackson,
• Martin F. Kaiser

Affiliations

Niels Weinhold

Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg

Hans J. Salwender

Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg

David A. Cairns

Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds

Marc S. Raab

Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg

George Waldron

Division of Genetics and Epidemiology, The Institute of Cancer Research, London

Igor W. Blau

Medical Clinic, Charité University Medicine Berlin, Berlin

Uta Bertsch

Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg

Thomas Hielscher

Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg

Gareth J. Morgan

Perlmutter Cancer Center, NYU Langone Health, New York

Anna Jauch

Institute of Human Genetics, University of Heidelberg, Heidelberg

Faith E. Davies

Perlmutter Cancer Center, NYU Langone Health, New York

Mathias Hänel

Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz

Gordon Cook

Leeds Institute of Cancer and Pathology, University of Leeds, Leeds

Christoph Scheid

Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne

Richard Houlston

Division of Genetics and Epidemiology, The Institute of Cancer Research, London

Hartmut Goldschmidt

Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg

Graham Jackson

Department of Haematology, University of Newcastle, Newcastle Upon Tyne

Martin F. Kaiser

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom; Department of Haematology, The Royal Marsden Hospital, London